explore -WSS

explore

author：hotspot 2025-09-27 13:05:01 - browse：468

Person wearing a smart watch. -- first opinion coverage from STAT — Adobe

The Apple Watch has secured a new qualification from the Food and Drug Administration that could make the smartwatch an appealing tool for medical device companies hoping to illustrate the benefits of a common heart procedure.

Last week, the Apple Watch’s Atrial Fibrillation History feature became the first digital tool qualified under the Medical Device Development Tools (MDDT) program. Released in 2022, the feature estimates a user’s A-fib burden, or how much time they spend in atrial fibrillation, which is an irregular heart rhythm that can cause shortness of breath and fatigue, and is also linked to an increased risk of stroke.

The qualification means that FDA has determined in advance that sponsors can use the feature as a secondary endpoint in clinical trials without having to do additional work. Specifically, the Apple Watch is qualified for use as a secondary endpoint in clinical trials for cardiac ablation devices, which reduce the electrical signals that cause A-fib by scarring the heart with extreme heat or cold energy. Pulsed field ablation is the latest version of the technology, using a controlled electric field to scar tissue rather than the riskier thermal energy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Weight loss drug costs may need more research, senator suggests

WSS

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Roche subsidiary Foundation Medicine opens new headquarters

CRISPR pioneers react to Casgevy, first gene

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

entertainment

explore

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

23andMe had bad news about my health. I wish a person had delivered it

Wegovy, Zepbound and weight loss drugs that preserve muscle

New air purifier tech could be key to improving indoor air quality

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

DIEP, the 'gold standard' of breast reconstruction, is under threat

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

DIEP, the 'gold standard' of breast reconstruction, is under threat

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Heart attack and stroke risk calculators need revising

Decaf coffee targeted by food safety group under obscure FDA rule

leisure time

Readout Newsletter: Merck, Vertex, and Viking updates

There's no autism epidemic. It's an autism diagnosis epidemic

Ransomware attacks on hospitals: Study outlines patient impact

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Merck drug for rare lung condition set for approval in U.S.

Study says nonprofit hospitals fall short in charity care spending

hotspot

focus

hotspot

focus